Vanguard Group Inc Harpoon Therapeutics, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.6 - $1.41 $310 - $730	518 Added 0.04%	1,153,148 $841,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $2.56 $49,933 - $135,989	-53,121 Reduced 4.41%	1,152,630 $1.12 Million
Q2 2022 Aug 12, 2022	SELL	$1.78 - $5.02 $146,762 - $413,904	-82,451 Reduced 6.4%	1,205,751 $2.3 Million
Q1 2022 May 13, 2022	BUY	$3.54 - $8.08 $121,747 - $277,887	34,392 Added 2.74%	1,288,202 $6.4 Million
Q4 2021 Feb 14, 2022	SELL	$5.69 - $7.83 $184,196 - $253,472	-32,372 Reduced 2.52%	1,253,810 $9.47 Million
Q3 2021 Nov 12, 2021	BUY	$7.88 - $14.0 $239,055 - $424,718	30,337 Added 2.42%	1,286,182 $10.2 Million
Q2 2021 Aug 13, 2021	BUY	$13.81 - $23.25 $17.3 Million - $29.2 Million	1,255,845 New	1,255,845 $17.4 Million

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.